Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis

BACKGROUND: Regorafenib (REG) is an oral multikinase inhibitor used in colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma. Several adverse events (AEs) are commonly reported during REG administration, and strategies for managing AEs in everyday clinical practice include...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Nannini, Margherita, Novelli, Marco, Dalia Ricci, Angela, Scioscio, Valerio Di, Pantaleo, Maria Abbondanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343359/
https://www.ncbi.nlm.nih.gov/pubmed/32684988
http://dx.doi.org/10.1177/1758835920936932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343359/
https://www.ncbi.nlm.nih.gov/pubmed/32684988
http://dx.doi.org/10.1177/1758835920936932

Ejemplares similares